Pri bolnikih, zdravljenih z rituksimabom, so opazili značilna znižanja v indeksu nezmožnosti (HAQ - DI), utrujenosti (FACIT- F) (preglednica 9) in izboljšanje v fizični in mentalni domeni zdravja SF- 36, v primerjavi z bolniki, ki so se zdravili le z metotreksatom (SF- 36 fizični 5, 8 v primerjavi z 0, 9, SF- 36 mentalni 4, 7 v primerjavi z 1, 3; študija 1).
Significant reductions in disability index (HAQ-DI), fatigue (FACIT-F) (Table 9), and improvement in both the physical and mental health domains of the SF-36 were observed in patients treated with rituximab compared to patients treated with methotrexate alone (SF-36 Physical 5.8 vs. 0.9, SF-36 Mental 4.7 vs. 1.3, respectively, Study 1).